 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 2562 | 回復(fù): 21 | |||||
| 【獎(jiǎng)勵(lì)】 本帖被評(píng)價(jià)18次，作者anruoka增加金幣 14.2 個(gè) | |||||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | |||||
[資源]
FDA 2015年4月28日 biosimilar 生物仿制藥三份新的指導(dǎo)原則出爐
|
|||||
|
FDA Final Guidance for Determining Biosimilarity On April 28, 2015, the U.S. Food and Drug Administration (FDA) released the much-anticipated final guidance documents related to implementation of the Biologics Price Control and Innovation Act of 2009 (BPCIA). Not surprisingly, the FDA’s three final guidance documents are substantially similar to the draft guidance issued in February 2012, discussed here, and reflect the FDA’s recent statements and actions leading to the approval of Sandoz’s Zarxio® product (filgrastim-sndz). The three final guidance documents can be found here: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (“SC”) (http://www.fda.gov/downloads/Dru ... ces/UCM291128.pdf); Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product (“QC”) (http://www.fda.gov/downloads/Dru ... ces/UCM291134.pdf); and Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 (“Q & A”) (http://www.fda.gov/downloads/Dru ... ces/UCM444661.pdf). The final guidance documents address broad concepts associated with demonstrating biosimilarity, including an emphasis on structural and functional characterization (SC at 9-11), human pharmacokinetic (PK) and pharmacodynamic (PD) data (SC at 13-17), comparative human clinical studies if there is “residual uncertainty” regarding clinically meaningful differences (SC at 18-20), non-U.S. licensed reference product comparators (SC at 6), extrapolation across indications (SC at 21-22); expression systems and manufacturing processes (QC at 10-11), analysis of the reference product (QC at 14-15), and analysis of the finished drug product (QC at 15-16). The final guidance documents do not, however, address interchangeability, as the FDA indicated that “[g]eneral scientific issues relating to the demonstration of interchangeability will be addressed separately.” (SC at 3, n.6.) Like the draft guidance, the final guidance recommends that biosimilar applicants utilize a “stepwise approach to developing data and information needed to support a demonstration of biosimilarity.” (SC at 7.) According to the FDA, this stepwise approach will help the applicant and the agency evaluate “the extent to which . . . residual uncertainty” remains concerning the biosimilarity of the proposed product to the reference product. (Id.) As part of this stepwise approach, the FDA “encourages sponsors to consult extensively with the Agency . . . throughout development as needed.” (SC at 8.) Indeed, the FDA indicated that early discussion with the FDA “will facilitate biosimilar development.” (SC at 23.) The FDA also reiterated its commitment to considering the “totality-of-the-evidence” when evaluating the data and information contained in a biosimilar application and will apply a “risk-based approach.” (SC at 8.) Applying the totality-of-the-evidence approach, the FDA indicated that an applicant could still demonstrate biosimilarity even if there are formulation or minor structural differences, so long those differences do not result in a “clinically meaningful” difference between the biosimilar and reference product. (Id.) The FDA’s implementation of the totality-of-the-evidence approach can be seen in the Agency’s recent review and approval of Zarxio®, where the review committee relied on Zarxio’s extensive use in Europe and the fact that Sandoz was able to establish biosimilarity despite using a different buffering system. Although human comparative clinical studies will likely be needed, at least in the immediate future, the FDA did indicate that such studies might only be needed “to support a demonstration of biosimilarity if there is residual uncertainty about whether there are clinically meaningful differences between the proposed product and the reference product” after conducting structural and functional characterizations, animal testing, human PK and PD studies and clinical immunogenicity assessment. (SC at 18.) “A sponsor should provide a scientific justification if it believes that a comparative clinical study is not necessary.” (Id.) Biosimilar development is being conducted on a global scale with several products already on the market in different countries. In view of this reality and the BPCIA’s requirement that a proposed product must be biosimilar to a single reference product previously licensed by the FDA, potential biosimilar applicants want to know whether the FDA would allow comparison of animal and human clinical data to a non-U.S.-licensed product. According to the FDA, the short answer is “Yes.” (Q&A at 8; SC at 7.) The FDA made clear however, that “as a scientific matter,” an application must contain at least one PK study and, if appropriate, at least one PD study comparing the biosimilar product to the U.S.-licensed product. (Q&A at 8.) If comparisons to a non-U.S.-licensed product are made, the applicant “should provide adequate data or information to scientifically justify the relevance of these comparative data to an assessment of biosimilarity and establish an acceptable bridge to the U.S.-licensed reference product.” (Q&A at 8; SC at 6.) As we now know from the recent approval of Zarxio®, the FDA will allow extrapolations to other indications if the proposed product meets the requirements for licensure as a biosimilar. In order to extrapolate, applicants “need to provide sufficient scientific justification” for such an extrapolation, and should address the mechanism of action(s) in each additional indication, PK, bio-distribution, immunogenicity, and expected toxicities of the biosimilar product in different patient populations. (SC at 21.) Finally, the FDA provided contact information if an applicant has a question about its proposed biosimilar development program. If the reference product is regulated by the Center for Drug Evaluation and Research (CDER), applicants are instructed to contact the Therapeutic Biologics and Biosimilars Team at 301-796-0700. If the reference product is regulated by the Center for Biologics Evaluation and Research (CBER), applicants should contact the Office of Communication, Outreach, and Development at 800-835-4709 or 240-402-7800, or email ocod@fda.hhs.gov. Finally, with general questions concerning the FDA’s implementation of the BPCIA, applicants and reference product sponsors should contact Sandra Benton in CDER’s Office of Medical Policy at 301-796-2500. With the recent approval of Zarxio®, and several additional biosimilar applications in the queue from Celltrion/Hospira (biosimilar to Remicade®  , Apotex (biosimilar to Neupogen®, and Hospira (biosimilar to Epogen® and Procrit®, the FDA should provide, over the coming months, further insights on the requirements necessary to obtain approval of much more complex biosimilar products. |
回復(fù)此樓» 本帖附件資源列表
-
歡迎監(jiān)督和反饋：小木蟲僅提供交流平臺(tái)，不對(duì)該內(nèi)容負(fù)責(zé)。
本內(nèi)容由用戶自主發(fā)布，如果其內(nèi)容涉及到知識(shí)產(chǎn)權(quán)問題，其責(zé)任在于用戶本人，如對(duì)版權(quán)有異議，請(qǐng)聯(lián)系郵箱：xiaomuchong@tal.com - 附件 1 : Quality_Considerations_in_Demonstrating_Biosimilarity_to_a_Reference_Protein_Product.pdf
- 附件 2 : Scientific_Considerations_in_Demonstrating_Biosimilarity_to_a_Reference_Product.pdf
- 附件 3 : Biosimilars=Questions_and_Answers_Regarding_Implementation_of_the_Biologics_Price_Competition_and_Innovation_Act_of_2009.pdf
2015-05-05 15:24:13, 144.19 K
2015-05-05 15:24:14, 169.02 K
2015-05-05 15:24:22, 106.84 K
» 收錄本帖的淘帖專輯推薦
 仿制藥研發(fā)申報(bào) | 生物醫(yī)藥操作規(guī)程 | 藥-提升,要-努力,鑰-這里 |
» 猜你喜歡
二糖的糖脂，合成后sephadex LH-20分離不出來，求助
已經(jīng)有1人回復(fù)
-
南方醫(yī)科大學(xué)珠江醫(yī)院肖計(jì)生課題組招收博士生 （2026年入學(xué)）
已經(jīng)有2人回復(fù)
-
藥物學(xué)論文潤(rùn)色/翻譯怎么收費(fèi)?
已經(jīng)有222人回復(fù)
-
349藥學(xué)專碩105500求調(diào)劑
已經(jīng)有0人回復(fù)
-
求調(diào)劑
已經(jīng)有1人回復(fù)
-
298求調(diào)劑一志愿中海洋
已經(jīng)有3人回復(fù)
-
藥學(xué)調(diào)劑申請(qǐng)自薦信，一志愿中南大學(xué)
已經(jīng)有1人回復(fù)
-
藥學(xué)349專碩求調(diào)劑
已經(jīng)有1人回復(fù)
-
錦州醫(yī)科大學(xué)藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有0人回復(fù)
-
錦州醫(yī)科大學(xué)藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有1人回復(fù)
-
《左乙拉西坦注射液制備工藝研究、質(zhì)量控制和穩(wěn)定性研究》下載
已經(jīng)有1人回復(fù)
» 本主題相關(guān)價(jià)值貼推薦，對(duì)您同樣有幫助:
- 聚焦生物仿制藥系列
已經(jīng)有6人回復(fù)
1949stone
榮譽(yù)版主 (知名作家)
- 應(yīng)助: 95 (初中生)
- 貴賓: 2.38
- 金幣: 2627.9
- 帖子: 9830
- 在線: 2692.8小時(shí)
- 蟲號(hào): 765987
3樓2015-05-05 23:07:34
9樓2015-05-07 22:30:46
簡(jiǎn)單回復(fù)
2015-05-05 17:14
回復(fù)
五星好評(píng) 頂一下，感謝分享！
2015-05-05 23:11
回復(fù)
五星好評(píng) 頂一下，感謝分享！
wang_q_h5樓
2015-05-06 12:30
回復(fù)
三星好評(píng) 頂一下，感謝分享！
2015-05-06 22:38
回復(fù)
五星好評(píng) 頂一下，感謝分享！
2015-05-07 09:10
回復(fù)
五星好評(píng) 
2015-05-07 21:46
回復(fù)
五星好評(píng) 頂一下，感謝分享！
cccu3310樓
2015-05-08 00:43
回復(fù)
五星好評(píng) 頂一下，感謝分享！
tangjianju11樓
2015-05-08 11:05
回復(fù)
五星好評(píng) 頂一下，感謝分享！
wayky12樓
2015-05-08 15:21
回復(fù)
五星好評(píng) 頂一下，感謝分享！
mazhenggen13樓
2015-05-08 18:09
回復(fù)
五星好評(píng) 頂一下，感謝分享！
wangshui14樓
2015-05-09 06:16
回復(fù)
五星好評(píng) 頂一下，感謝分享！
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 復(fù)試調(diào)劑 +4 | z1z2z3879 2026-03-14 | 6/300 |
|
|---|---|---|---|---|
|
|
[考研] 【考研調(diào)劑】化學(xué)專業(yè) 281分，一志愿四川大學(xué)，誠(chéng)心求調(diào)劑 +5 | 吃吃吃才有意義 2026-03-19 | 5/250 |
|
|
[考研] 266求調(diào)劑 +5 | 陽陽哇塞 2026-03-14 | 10/500 |
|
|
|
[考研] 材料與化工求調(diào)劑 +7 | 為學(xué)666 2026-03-16 | 7/350 |
|
|
|
[考研] 324分 085600材料化工求調(diào)劑 +3 | llllkkkhh 2026-03-18 | 3/150 |
|
|
|
[考研] 328求調(diào)劑，英語六級(jí)551，有科研經(jīng)歷 +4 | 生物工程調(diào)劑 2026-03-16 | 12/600 |
|
|
|
[考研] 304求調(diào)劑 +6 | 司空. 2026-03-18 | 6/300 |
|
|
|
[考研] 085601專碩，總分342求調(diào)劑，地區(qū)不限 +5 | share_joy 2026-03-16 | 5/250 |
|
|
|
[考研] 0703化學(xué)求調(diào)劑 總分331 +3 | ZY-05 2026-03-13 | 3/150 |
|
|
|
[考研] 278求調(diào)劑 +5 | 煙火先于春 2026-03-17 | 5/250 |
|
|
|
[考研] 301求調(diào)劑 +4 | A_JiXing 2026-03-16 | 4/200 |
|
|
|
[考研] 290求調(diào)劑 +3 | p asserby. 2026-03-15 | 4/200 |
|
|
|
[考研] 一志愿蘇州大學(xué)材料工程（085601）專碩有科研經(jīng)歷三項(xiàng)國(guó)獎(jiǎng)兩個(gè)實(shí)用型專利一項(xiàng)省級(jí)立項(xiàng) +6 | 大火山小火山 2026-03-16 | 8/400 |
|
|
|
[考研] 一志愿南京大學(xué)，080500材料科學(xué)與工程，調(diào)劑 +4 | Jy? 2026-03-16 | 4/200 |
|
|
|
[考研] 0854控制工程 359求調(diào)劑 可跨專業(yè) +3 | 626776879 2026-03-14 | 9/450 |
|
|
|
[考研] 321求調(diào)劑 +5 | 大米飯！ 2026-03-15 | 5/250 |
|
|
|
[考研] 070300化學(xué)學(xué)碩求調(diào)劑 +6 | 太想進(jìn)步了0608 2026-03-16 | 6/300 |
|
|
|
[考研] 求老師收留調(diào)劑 +4 | jiang姜66 2026-03-14 | 5/250 |
|
|
|
[考研] 中科大材料與化工319求調(diào)劑 +3 | 孟鑫材料 2026-03-14 | 3/150 |
|
|
|
[考研] 中科大材料專碩319求調(diào)劑 +3 | 孟鑫材料 2026-03-13 | 3/150 |
|